Nav: Home

Study: Rare patients with sickle cell disease live nearly twice national average

October 04, 2016

(WASHINGTON, Oct. 4, 2016) -- With a national median life expectancy of 42-47 years, people with sickle cell disease (SCD) face many challenges, including severe pain episodes, stroke, and organ damage. Compounding these complications is that SCD -- an inherited, lifelong blood disorder characterized by rigid and sickle-shaped red blood cells that stick to the blood vessels, blocking blood flow -- has only one FDA-approved treatment, no widely available cure, and some people may have limited access to appropriate care.

However, a new report published online today in Blood, the Journal of the American Society of Hematology (ASH), shows that some people with mildly symptomatic SCD may live long lives with proper management of the disease, including strong family support and strict adherence to medication and appointments. This analysis of four case studies details the outcomes of four women with milder forms of SCD who have far surpassed the U.S. median of 47 years old for women with the disease, instead living as long as 86 years.

Report author Samir K. Ballas, MD, Professor Emeritus in the Department of Medicine at Sidney Kimmel Medical College at Thomas Jefferson University in Philadelphia, hopes that this example can serve as a blueprint for others living with SCD. "For those with mild forms of SCD, these women show that lifestyle modifications may improve disease outcomes," said Dr. Ballas. Of the women described in this report, three were treated at the Sickle Cell Center of Thomas Jefferson University, and one in Brazil's Instituto de Hematologia Arthur de Siqueira Cavalcanti in Rio de Janeiro. Though they had dissimilar ancestries (two African American, one Italian American, and one African Brazilian), all led healthy lives bolstered by long-term family support, to which Dr. Ballas attributes their long lives and high quality of life.

"It is very likely that their healthy lifestyles were important contributors to their longevity. All of the women were non-smokers who consumed little to no alcohol and maintained a normal body mass index. This was coupled with a strong compliance to their treatment regimens and excellent family support at home," said Dr. Ballas.

For this report, treatment compliance was based on observations by health care providers, including study authors. Family support was defined as having a spouse or child who provided attentive, ongoing care.

Another common factor among these four women is that they had what Dr. Ballas called "desirable" disease states. "These women never had a stroke, never had recurrent acute chest syndrome, had a relatively high fetal hemoglobin count [which helps to prevent cells from sickling], and had infrequent painful crises. Patients like this usually -- but not always -- experience relatively mild SCD, and they live longer with better quality of life."

As they had relatively mild disease states, none of the women were qualified to receive treatment with hydroxyurea (HU), the only FDA-approved treatment for adults with SCD. Accordingly, these patients received standard treatment including hydration, vaccination (including annual flu shots), and blood transfusion and analgesics as needed. Patients were encouraged to attend regular follow-up visits, not to smoke, watch their weight, and maintain a support system as needed.

Dr. Ballas was quick to point out, however, that this does not mean these women lived crisis-free lives. Each experienced disease-related complications necessitating medical attention, like occasional acute chest syndrome, a problem that can cause fever, cough, excruciating pain, and shortness of breath.

It is worth noting, said Dr. Ballas, that the report does have limitations. For one, there were only four participants, all of whom were women. "Adult females with SCD generally live longer than males, but we do not know why. One possibility is that women tend to have relatively lower blood viscosity due to their lower hemoglobin level compared to males." That said, Dr. Ballas was quick to point out that this does not mean men cannot benefit from a healthy lifestyle.

To that end, Dr. Ballas hopes that patients who have defied expectations like these four women can serve as positive examples for SCD patients of all ages: "I would often come out to the waiting room and find these ladies talking with other SCD patients, and I could tell that they gave others hope, that just because they have SCD does not mean that they are doomed to die by their 40s -- that if they take care of themselves, and live closely with those who can help keep them well, that there is hope for them to lead long, full lives."
-end-
Blood, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) , the world's largest professional society concerned with the causes and treatment of blood disorders.

ASH's mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.


American Society of Hematology

Related Sickle Cell Disease Articles:

Social determinant screening useful for families with pediatric sickle cell disease
Individuals with sickle cell disease (SCD) face the burdens of chronic illness and often racial disparities, both of which may increase vulnerability to adverse social determinants of health (SDoH).
Uncovering new therapeutic targets for airway inflammation in sickle cell disease
A new study by De, Agrawal, Morrone et al, challenges the common notion that airway in-flammation in Sickle Cell Disease (SCD) is secondary to asthma, even though the two disor-ders often coexist.
Researchers develop new method to rapidly, reliably monitor sickle cell disease
Researchers have developed a rapid and reliable new method to continuously monitor sickle cell disease using a microfluidics-based electrical impedance sensor.
Sickle cell disease needs more attention
Article signed by researchers affiliated with institutions in the US, UK, Ghana and Brazil highlights recent progress in diagnosis and treatment but warns that more screening of newborns is needed.
New genetic weapons challenge sickle cell disease
Researchers advancing gene-editing techniques to help patients with sickle cell disease discover an unexpected boost in fetal hemoglobin production, which mutes the effect of the disease.
Routine sickle cell disease screening among migrants may help save lives
Hematologists are zeroing in on the escalating humanitarian crisis in southern Europe by assessing the burden of blood disorders among refugees and identifying strategies to facilitate more timely identification and treatment of refugees with sickle cell disease (SCD).
Most precise measurements of sickle cell disease building blocks could lead to new treatments
In a breakthrough study of sickle cell disease, biomedical engineers in the University of Minnesota College of Science and Engineering have revealed that the building blocks of the disease are much less efficient at organizing than previously thought.
The silence of sickle cell disease
Silent strokes are a common symptom of sickle cell disease, though they can be debilitating.
Study affirms challenges in managing severe pain of sickle cell disease
In a study tracking the severe crisis pain of sickle cell disease and its management in 73 adults over a period of a year, Johns Hopkins researchers found that even among those on high doses of daily at-home opioids, a persistent subset was more likely to seek emergency hospital care for crisis pain and was less likely to have the pain controlled by intensive treatment.
Enzyme identified as possible novel drug target for sickle cell disease, Thalassemia
Medical researchers have identified a key signaling protein that regulates hemoglobin production in red blood cells, offering a possible target for a future innovative drug to treat sickle cell disease.
More Sickle Cell Disease News and Sickle Cell Disease Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

Risk
Why do we revere risk-takers, even when their actions terrify us? Why are some better at taking risks than others? This hour, TED speakers explore the alluring, dangerous, and calculated sides of risk. Guests include professional rock climber Alex Honnold, economist Mariana Mazzucato, psychology researcher Kashfia Rahman, structural engineer and bridge designer Ian Firth, and risk intelligence expert Dylan Evans.
Now Playing: Science for the People

#541 Wayfinding
These days when we want to know where we are or how to get where we want to go, most of us will pull out a smart phone with a built-in GPS and map app. Some of us old timers might still use an old school paper map from time to time. But we didn't always used to lean so heavily on maps and technology, and in some remote places of the world some people still navigate and wayfind their way without the aid of these tools... and in some cases do better without them. This week, host Rachelle Saunders...
Now Playing: Radiolab

Dolly Parton's America: Neon Moss
Today on Radiolab, we're bringing you the fourth episode of Jad's special series, Dolly Parton's America. In this episode, Jad goes back up the mountain to visit Dolly's actual Tennessee mountain home, where she tells stories about her first trips out of the holler. Back on the mountaintop, standing under the rain by the Little Pigeon River, the trip triggers memories of Jad's first visit to his father's childhood home, and opens the gateway to dizzying stories of music and migration. Support Radiolab today at Radiolab.org/donate.